# SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

> **NCT00440271** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 33 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** tipranavir
- **DRUG:** ritonavir
- **DRUG:** Optimized Background Regimen (OBR)

## Key facts

- **NCT ID:** NCT00440271
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** 2008-10
- **Final completion:** —
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440271, "SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00440271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*